DON-A (Domperidone) is a dopamine receptor (D2) antagonist. DON-A (Domperidone) is a selective peripheral dopamine antagonist at the D2
dopamine receptor in the Chemo-receptor Trigger Zone (CTZ) and stomach. DON-A (Domperidone) does not readily enter the central
nervous system (the chemoreceptor trigger zone is considered to lie outside the blood brain barrier). DON-A (Domperidone) increases
spontaneous gastric activity and antagonizes dopamine inhibition of gastric emptying. DON-A (Domperidone) has been shown to increase
lower esophageal sphincter pressure and promotes esophageal and antral peristalsis and also increases pyloric dilatation. DON-A (Domperidone)
increases the frequency, amplitude, duration of duodenal contraction and reduces the small bowel transit time. DON-A (Domperidone) has no
acetylcholine like effect.
DON-A Paediatric Drops
DON-A (Domperidone) should be taken 15-30 minutes before a meal. The usual recommended oral dose is as follows:
Tablet/ Suspension/ Paediatric drops :
Adult: 10-20 mg (1-2 DON-A tablet or 10-20 ml DON-A suspension) every 4-8 hours.
Elderly : Same as for adults.
Children: 0.2-0.4 mg/kg body weight (2-4 ml suspension or 0.4-0.8 ml
Paediatric drops/ 10 kg body weight) every 4-8 hours.
By rectum in suppositories :
Adults (including elderly) : 30-60 mg every 4-8 hours.
Children : The maximum daily dose rectally in children?s is 30 mg for
those weighting 10 to 25 kg. Dose may be divided throughout day if necessary.
Maximum period of treatment is 12 weeks.